TIM-3 expression induces resistance to PD-1 inhibitor in G-CSF-producing lung spindle cell carcinoma: A case report

Thorac Cancer. 2023 Dec;14(36):3556-3560. doi: 10.1111/1759-7714.15149. Epub 2023 Nov 5.

Abstract

Lung spindle cell carcinoma is an aggressive subtype of pleomorphic lung cancer resistant to cytotoxic chemotherapy. Programmed cell death-1 (PD-1) inhibitors have been reported to have clinical effects in patients with spindle cell carcinoma; however, the resistance mechanism to PD-1 inhibitors is yet to be fully elucidated. Herein, we report the case of an 88-year-old man with G-CSF-producing spindle cell carcinoma who acquired resistance to PD-1/PD-ligand 1 (L1) inhibitor in an early setting after a remarkable response. A histopathological review of the resistant specimen revealed a low count of CD8+ T cells and a predominant presence of M2 and TIM-3+ macrophages, indicating the presence of an immunosuppressive microenvironment. Our findings suggest a novel resistance mechanism to PD-1/PD-L1 inhibitors in G-CSF-producing spindle cell carcinoma.

Keywords: M2 macrophage; TIM-3; acquired resistance; immune checkpoint blockade; spindle cell carcinoma.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • B7-H1 Antigen / metabolism
  • CD8-Positive T-Lymphocytes / metabolism
  • Carcinoma*
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Hepatitis A Virus Cellular Receptor 2 / therapeutic use
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Lung / pathology
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / pathology
  • Male
  • Programmed Cell Death 1 Receptor / metabolism
  • Tumor Microenvironment

Substances

  • Immune Checkpoint Inhibitors
  • Granulocyte Colony-Stimulating Factor
  • Hepatitis A Virus Cellular Receptor 2
  • Programmed Cell Death 1 Receptor
  • B7-H1 Antigen